Multiple Myeloma Face-Off: Memorial Sloan Kettering vs Dana-Farber

Steven Frommeyer introduces the two teams of competing physicians participating in Cancer Network® Face-off.

Clifton Mo, MD, presents data from the INSURE study, a pooled analysis evaluating patients with relapsed/refractory multiple myeloma treated with Ixazomib-Lenalidomide-Dexamethasone (IRd).

Dr Clifton Mo fields questions from the Memorial Sloan Kettering team about his presentation on IRd in relapsed/refractory multiple myeloma.

Shonali Midha, MD, highlights data from the DREAMM-5 study during her presentation on the use of belantamab mafodotin for late relapse multiple myeloma.

Dr Shonali Midha continues her analysis of belantamab mafodotin with a look at data on real-world use in R/R MM since its FDA approval in August 2020.

Malin Hultcrantz, MD, PhD, questions Shonali Midha, MD, about the data she presented on belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Experts from leading institutions debate the latest advances in multiple myeloma.